Evidence analysisNovember 4, 2026Health & Science
Veterinary medicines European public assessment report (EPAR): Eravac, rabbit haemorrhagic disease vaccine (inactivated), Status: Withdrawn

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Health & Science Evidence Dossier: Withdrawal of Eravac Rabbit Haemorrhagic Disease Vaccine
What is established
Eravac was a veterinary vaccine authorised within the European Union for protection against rabbit haemorrhagic disease virus type 2 (RHDV2). It was an inactivated viral vaccine developed to prevent a highly contagious and fatal disease in rabbits caused by RHDV2, strain V-1037. The vaccine had been approved by the European Medicines Agency (EMA), with initial marketing authorisation granted in 2016.
As of November 4, 2026, the marketing authorisation for Eravac has been officially withdrawn at the request of the marketing authorisation holder. The withdrawal is documented in the EMA’s Veterinary medicines European Public Assessment Report (EPAR), which provides regulatory details including assessment history and product information. The vaccine had been subject to some variations and assessments since initial authorisation, but the public documents do not indicate any regulatory action due to safety or efficacy concerns.
What the source claims
The EMA states that the withdrawal of marketing authorisation was requested by the holder of the authorisation. The EPAR indicates that the product status changed from authorised to withdrawn on October 23, 2026. The publicly available assessment reports and post-authorisation documents do not explicitly provide detailed reasons for the withdrawal.
The information highlights that the decision was not prompted by any EMA-imposed suspension or revocation but rather is a voluntary action initiated by the authorisation holder, which can sometimes reflect business decisions or strategic repositioning rather than safety concerns.
What may be missing from the usual framing
- Reasons for withdrawal: The publicly accessible EMA documentation does not clarify specific reasons for the withdrawal. Whether it was due to commercial considerations, manufacturing changes, shifts in market demand, or other external factors remains unclear.
- Impact on rabbit health management: The withdrawal of an authorised RHDV2 vaccine may affect veterinary practices and rabbit breeders, but the source does not discuss alternative vaccines available or the broader epidemiological context of RHDV2 circulation in Europe.
- Context of the vaccine market: There is no discussion of the competitive landscape for RHDV2 vaccines or whether newer formulations or alternative products have supplanted Eravac in the market.
Competing evidence or uncertainty
The evidence presented by EMA documents is straightforward concerning the withdrawal procedure but insufficient to determine the underlying reasons or implications fully.
There is no publicly available evidence from independent veterinary or scientific sources that contradict or elaborate on the EMA data regarding Eravac’s withdrawal. Without manufacturer statements or additional regulatory commentary, it is uncertain whether the withdrawal relates to production capacity, strategic business decisions, changes in disease patterns, or technical issues with the vaccine.
Additionally, information about whether withdrawal caused gaps in disease prevention or if substitutes were readily available to veterinarians remains unaddressed, constituting an area of uncertainty.
Why it matters
Rabbit haemorrhagic disease caused by RHDV2 is a serious health threat to domestic and wild rabbit populations across Europe, often with devastating mortality rates. Vaccines like Eravac constitute a key tool in controlling outbreaks and protecting animal welfare and economic interests in farming and pet ownership.
The voluntary withdrawal of an established vaccine may have practical consequences for disease control strategies, veterinary protocols, and the availability of viable prevention options. Understanding the reasons behind such regulatory changes informs stakeholders including veterinarians, rabbit breeders, researchers, and policymakers.
Moreover, transparency about vaccine withdrawals helps maintain public and professional trust in veterinary medicinal products and regulatory oversight.
What to verify next
- Seek official communications or statements from the marketing authorisation holder explaining their rationale for withdrawing Eravac.
- Investigate whether replacement vaccines for RHDV2 are available and recommended within the EU veterinary context post-Eravac withdrawal.
- Monitor veterinary epidemiological data about RHDV2 outbreaks to assess if this regulatory change impacts disease incidence or control measures.
- Consult veterinary professional associations or regulatory experts regarding the implications of the withdrawal for clinical practice.
- Review wider market trends and regulatory decisions on veterinary vaccines targeting RHDV2 to understand the broader industry context.
Readers are encouraged to consult the original European Medicines Agency source documentation for full details and official updates regarding the status of Eravac and other veterinary medicines.
Source & verification
Primary source: What's new · November 4, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…